SCHEMBL4336987

SCHEMBL4336987

Cc1ccc(C)c(-c2noc(N)c2-c2ccncc2)c1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPK14 Q16539 2/20 0.52
MLYCD O95822 1/20 0.45
RAB9A P51151 8/20 0.44
NPC1 O15118 7/20 0.44
MEN1 O00255 2/20 0.44
KMT2A Q03164 2/20 0.44
HSP90AA1 P07900 1/20 0.40
BRD4 O60885 1/20 0.39
TDO2 P48775 1/20 0.39
MAPK9 P45984 1/20 0.36
MAPK10 P53779 1/20 0.36
MAPK11 Q15759 1/20 0.36
LMNA P02545 1/20 0.36
CA1 P00915 1/20 0.36
CA2 P00918 1/20 0.36
CA4 P22748 1/20 0.36
CA7 P43166 1/20 0.36
LRRK2 Q5S007 1/20 0.36
GAA P10253 2/20 0.35
PTGS1 P23219 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4335463 0.86 MAPK14 (0.57) MAPK14MLYCDRAB9ANPC1MEN1
SCHEMBL4332040 0.83 MAPK14 (0.55) MAPK14MLYCDRAB9ANPC1HSP90AA1
SCHEMBL1876450 0.83 MAPK14 (0.54) MAPK14RAB9ANPC1MEN1KMT2A
SCHEMBL4341533 0.81 MAPK14 (0.72) MAPK14MLYCDRAB9ANPC1MEN1
SCHEMBL4346446 0.80 MAPK14 (0.62) MAPK14MLYCDRAB9ANPC1HSP90AA1
SCHEMBL4334970 0.80 MAPK14 (0.61) MAPK14MLYCDRAB9ANPC1MEN1
SCHEMBL4338473 0.79 MAPK14 (0.57) MAPK14MLYCDRAB9ANPC1BRD4
SCHEMBL4334913 0.78 MAPK14 (0.59) MAPK14MLYCDRAB9ANPC1HSP90AA1
SCHEMBL4334926 0.78 MAPK14 (0.52) MAPK14MLYCDHSP90AA1BRD4TDO2
SCHEMBL4329246 0.77 MAPK14 (0.66) MAPK14MLYCDRAB9ANPC1HSP90AA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8207203-B2 Pyridylisoxazole derivatives ASKA PHARMACEUTICAL CO., LTD. (JP) 2012-06-26 US disclosed
US-20090306145-A1 Pyridylisoxazole Derivatives ASKA PHARMACEUTICAL CO., LTD. (JP) 2009-12-10 US disclosed
EP-2036905-A1 PYRIDYLISOXAZOLE DERIVATIVE ASKA Pharmaceutical Co., Ltd. (JP) 2009-03-18 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090306145-A1 Pyridylisoxazole Derivatives CNKSR1, MAPK1, MAPK3 MAPK14 43/4885MLYCD 4475/4885RAB9A 2267/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.